Novo Nordisk

A deliberate way to prepare for potential Novo Nordisk ownership

Options 10 minutes to read
MicrosoftTeams-image (3)
Koen Hoorelbeke

Investment and Options Strategist

Summary:  If you’re positive on Novo Nordisk but hesitant to buy after the recent pull-back, there are ways to approach your entry more strategically. This article outlines a disciplined method that lets investors define the price at which they’re willing to become shareholders.


A deliberate way to prepare for potential Novo Nordisk ownership

Novo after a difficult year

Novo Nordisk’s US-listed shares (NVO:xnys) have struggled over the past year after an exceptionally strong multi‑year rally. The pull-back has created uncertainty for long-term investors who like the obesity and diabetes story but are hesitant to add exposure during a period of elevated volatility.

Novo Nordisk (NVO) weekly and daily price charts showing the recent correction and support forming around the 45–50 USD area.
Novo Nordisk has stabilised near the 45–50 USD zone after a volatile year, creating a potential reference area for long-term investors. Source: SaxoTraderGO

Recent price action shows the shares stabilising near the 45–50 area, a zone that has acted as short-term support. For investors who remain constructive on Novo but prefer a more deliberate entry point, a cash secured put offers a structured and financially disciplined approach.

This article focuses on the mechanics of the strategy. For a broader look at Novo’s fundamentals, see our colleague’s comparison of Novo Nordisk and Eli Lilly (see the related links section below this article).

What a cash secured put is

A cash secured put is a conservative options strategy designed for investors who are willing to buy shares at a predetermined price. You sell a put option at the strike level where you would be comfortable becoming a shareholder and keep enough cash aside to meet that obligation.

Two outcomes exist:

  • If the share price stays above the strike at expiry, the option typically expires worthless and you keep the premium.
  • If the price finishes below the strike, you must buy the shares at the strike, using the cash you reserved.

For long-term investors, this functions as a limit order that pays you a premium while you wait.

The Novo example: selling the December 45 put

Important note: The strategies and examples provided in this article are purely for educational purposes. They are intended to assist in shaping your thought process and should not be replicated or implemented without careful consideration. Every investor or trader must conduct their own due diligence and take into account their unique financial situation, risk tolerance, and investment objectives before making any decisions. Remember, investing in the stock market carries risk, and it's crucial to make informed decisions.

Below is the example setup based on current market conditions.

  • Underlying: Novo Nordisk (NVO:xnys)
  • Current share price in example: about USD 49
  • Option: Sell to open 45-strike put
  • Expiry: 19 December 2025
  • Premium: about USD 1.40 per share
  • Contract size: 100 shares
Options chain for Novo Nordisk (NVO:xnys) highlighting the December 19, 2025 put option at the 45 strike with notable open interest.
The 45-strike December put shows meaningful open interest, indicating a level closely watched by market participants. Source: SaxoTraderGO,

Key figures for this setup:

  • Cash reserved: USD 4,500 per contract
  • Premium received: USD 140
  • Effective entry price if assigned: 43.60
  • Premium yield over the period: roughly 3.1% for about 37 days (for comparison only)

This keeps the strategy simple and transparent. Investors set aside the full strike value and evaluate the trade as if they were placing a buy order at 45.

Why the 45 strike matters

The 45 level aligns with the short-term support visible on the charts. For many long-term investors, this is a more comfortable entry than buying directly at current levels.

There is also notable open interest at the 45 strike, as shown in the option chain. Open interest represents the number of outstanding contracts. High concentrations can behave as friction zones where market participants hedge and adjust positions. While not a predictive signal, it is a reference level many traders monitor.

Three potential outcomes at expiry

Using simple numbers helps clarify what each scenario may look like.

1. Novo stays above 45

If the share price remains above 45 at expiry, the put expires worthless. You keep the USD 140 premium. The return on the reserved USD 4,500 is about 3.1% for the period. You do not buy the shares, so if the market rallies significantly, you forgo that upside. You can repeat the strategy if you still want exposure.

2. Novo finishes slightly below 45

If Novo ends near the strike—for example at 44.50—you are assigned and purchase 100 shares at 45. After accounting for the premium, your effective cost is 43.60. You begin your long-term investment with a small buffer even though the stock declined during the holding period.

3. Novo declines sharply

If the shares fall substantially—for example to 35—you still must buy at 45. Your effective cost remains 43.60, and the loss resembles buying the stock outright at that level. A cash secured put does not shield you from company‑specific downside.

Payoff diagram for selling the 45-strike put on Novo Nordisk, marking the premium received and the break-even level at 43.60 USD.
The payoff profile of the 45-strike put illustrates the defined premium income and the effective entry price if assigned. Source: SaxoTraderGO,

Risks and considerations

A cash secured put is a conservative structure, but it still carries the full downside risk of owning an individual stock. Novo’s long-term prospects are linked to regulatory, competitive and pipeline developments, all of which can influence price behaviour.

Opportunity cost is another factor. If the shares rebound rapidly and never revisit the strike, you may miss the recovery. Position size is important: the obligation to buy 100 shares should fit comfortably within your portfolio.

Investors should also consider tax treatment, currency implications and personal suitability before implementing the strategy.

Practical steps

For investors wishing to implement the strategy:

  • Ensure you have sufficient cash to reserve for the obligation.
  • Locate Novo Nordisk (NVO:xnys) in the platform and open the options chain.
  • Select the 45 put expiring 19 December 2025.
  • Place a limit order to sell the option—around the bid or mid-price.
  • Monitor the position and be aware of the expiry date and key company developments.

A cash secured put allows long-term investors to pursue ownership at a defined price while generating income on cash held aside. It is a measured way to re-engage with Novo after a volatile period, with clear outcomes and transparent risk.

FAQ

  • What happens if I want to exit the position early?

You can close a short put at any time before expiry by buying back the option. The result may be a profit or a loss depending on where the option is trading.

  • Is the premium guaranteed?

You receive the premium upfront, but your final profit or loss depends on what happens between trade date and expiry, and whether you are assigned.

  • Can I repeat the strategy if I do not get the shares?

Yes. Many long-term investors sell puts repeatedly until they receive assignment at a price they are comfortable with.

  • Does this strategy protect me from large declines in Novo?

No. A cash secured put provides only a small buffer equal to the premium received. A sharp fall in the share price can still lead to substantial losses.

  • What if the option expires worthless?

You keep the full premium and remain uninvested. You can choose to sell another put or reconsider your entry strategy.

This content is marketing material and should not be regarded as investment advice. Trading financial instruments carries risks and historic performance is not a guarantee of future results.
The Author is permitted to wait at least 24 hours from the time of the publication before they trade the instruments themselves.
The instrument(s) referenced in this content may be issued by a partner, from whom Saxo receives promotional fees, payment or retrocessions. While Saxo may receive compensation from these partnerships, all content is created with the aim of providing clients with valuable information and options.
This content will not be changed or subject to review after publication.
Related articles/content             
Novo vs Lily | 12 Nov 2025
How investors are using collar strategies on some of the most-traded stocks | 10 Nov 2025
How to protect your stocks with options when markets get shaky | 7 Nov 2025
A smarter way to start investing in Rheinmetall - with more control and lower risk | 4 Nov 2025
Exploring a conservative way to buy Amazon shares at a lower level | 28 Oct 2025
What long-term Microsoft investors can do with short-term volatility | 27 Oct 2025
How investors can turn Alphabets volatility into opportunity | 23 Oct 2025
Cash-secured puts on Tesla - how expiry choice shapes risk and reward | 20 Oct 2025
How long-term investors can use ASML mini options ahead of earnings | 10 Oct 2025
Intel just jumped on Nvidias vote of confidence What now | 19 Sep 2025
Oracle - how long-term investors can earn extra income after the stocks big move | 18 Sep 2025
A lower-cost alternative to generate income on Nike - the poor man covered call | 8 Sep 2025
What long-term investors can do with Nike options ahead of earnings | 4 Sep 2025
Earnings around the corner - how to use a cash-secured put to set your Alibaba buy price | 13 Aug 2025
Disney - earn while you wait for your ideal entry price | 11 Aug 2025
An income idea for Palantir shareholders | 1 Aug 2025
Collect monthly income from UBS - a beginners guide to covered calls | 31 Jul 2025
How Amazon shareholders can collect extra income before earnings | 29 Jul 2025
After the drop - two smarter ways to invest in ASML today | 18 Jul 2025
The overlooked strategy turning cash into consistent income | 11 Jul 2025
Getting paid to buy Novo Nordisk - earn income while waiting for a better price | 8 Jul 2025
Get paid to wait - how to earn income while preparing to buy Palantir shares | 30 Jun 2025
There s another way to buy SAP - one that pays you | 27 Jun 2025
How to get paid for your patience - Using cash-secured puts to invest in Intel 23 Jun 2025
How to turn your Intel shares into an income machine - even in a tough market | 20 Jun 2025
Already own Logitech - or want to - There is a smarter way to invest either way
How long-term investors can earn income or buy Alibaba at a discount with options
Earning extra income and buying at a discount - Covered calls and cash-secured puts on Palantir
How to earn extra Income from your Nestle shares - without taking on unnecessary risk
How to use cash-secured puts to buy UBS stock - or earn income while you wait
Learn how to generate income from ASML shares using MINI-options
Learn how you can earn income or buy Bitcoin at a discount
How a covered call on AMD generates extra income for long-term investors
Learn how you can earn income or buy Bitcoin-exposure at a discount

Guide on long-term options for strategic portfolio management
Assignment explained - 01 - what every options trader and investor should know
Assignment explained - 02 - how to avoid assignment
Assignment explained - 03 - how to use option assignment to your advantage
Assignment explained - 04 - option assignment cheat sheet
More from the author             

Quarterly Outlook

01 /

  • Q4 Outlook for Investors: Diversify like it’s 2025 – don’t fall for déjà vu

    Quarterly Outlook

    Q4 Outlook for Investors: Diversify like it’s 2025 – don’t fall for déjà vu

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Q4 Outlook for Traders: The Fed is back in easing mode. Is this time different?

    Quarterly Outlook

    Q4 Outlook for Traders: The Fed is back in easing mode. Is this time different?

    John J. Hardy

    Global Head of Macro Strategy

    The Fed launched a new easing cycle in late Q3. Will this cycle now play out like 2000 or 2007?
  • Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Quarterly Outlook

    Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    Quarterly Outlook

    Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    John J. Hardy

    Global Head of Macro Strategy

    After the chaos of Q2, the quarter ahead should get a bit more clarity on how Trump 2.0 is impacting...
  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

The information on or via the website is provided to you by Saxo Bank (Switzerland) Ltd. (“Saxo Bank”) for educational and information purposes only. The information should not be construed as an offer or recommendation to enter into any transaction or any particular service, nor should the contents be construed as advice of any other kind, for example of a tax or legal nature.

All trading carries risk. Loses can exceed deposits on margin products. You should consider whether you understand how our products work and whether you can afford to take the high risk of losing your money.

Saxo Bank does not guarantee the accuracy, completeness, or usefulness of any information provided and shall not be responsible for any errors or omissions or for any losses or damages resulting from the use of such information.

The content of this website represents marketing material and is not the result of financial analysis or research. It has therefore not been prepared in accordance with directives designed to promote the independence of financial/investment research and is not subject to any prohibition on dealing ahead of the dissemination of financial/investment research.

Saxo Bank (Schweiz) AG
The Circle 38
CH-8058
Zürich-Flughafen
Switzerland

Contact Saxo

Select region

Switzerland
Switzerland

All trading carries risk. Losses can exceed deposits on margin products. You should consider whether you understand how our products work and whether you can afford to take the high risk of losing your money. To help you understand the risks involved we have put together a general Risk Warning series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. The KIDs can be accessed within the trading platform. Please note that the full prospectus can be obtained free of charge from Saxo Bank (Switzerland) Ltd. or the issuer.

This website can be accessed worldwide however the information on the website is related to Saxo Bank (Switzerland) Ltd. All clients will directly engage with Saxo Bank (Switzerland) Ltd. and all client agreements will be entered into with Saxo Bank (Switzerland) Ltd. and thus governed by Swiss Law. 

The content of this website represents marketing material and has not been notified or submitted to any supervisory authority.

If you contact Saxo Bank (Switzerland) Ltd. or visit this website, you acknowledge and agree that any data that you transmit to Saxo Bank (Switzerland) Ltd., either through this website, by telephone or by any other means of communication (e.g. e-mail), may be collected or recorded and transferred to other Saxo Bank Group companies or third parties in Switzerland or abroad and may be stored or otherwise processed by them or Saxo Bank (Switzerland) Ltd. You release Saxo Bank (Switzerland) Ltd. from its obligations under Swiss banking and securities dealer secrecies and, to the extent permitted by law, data protection laws as well as other laws and obligations to protect privacy. Saxo Bank (Switzerland) Ltd. has implemented appropriate technical and organizational measures to protect data from unauthorized processing and disclosure and applies appropriate safeguards to guarantee adequate protection of such data.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.